Related Experiment Videos
Management of hypercholesterolaemia in the patient with diabetes
1Glasgow Royal Infirmary, Scotland.
Insights
Coronary heart disease (CHD) is a major risk for type 2 diabetes patients. Aggressive lipid-lowering therapy, especially with statins, effectively reduces cardiovascular risk by improving lipid profiles.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Coronary heart disease (CHD) is the primary cause of mortality in type 2 diabetes patients.
- Type 2 diabetes often presents with dyslipidaemia, hypertension, and hyperglycaemia, increasing cardiovascular risk.
- Diabetic dyslipidaemia involves high triglycerides, low HDL-C, and small, dense LDL particles, all CHD risk factors.
Purpose of the Study:
- To review the role of lipid-lowering therapy in managing cardiovascular risk in type 2 diabetes.
- To highlight the effectiveness of statins and fibrates in addressing diabetic dyslipidaemia.
- To emphasize the potential of aggressive lipid management in reducing CHD events.
Main Methods:
- Review of retrospective subgroup analyses and prospective studies on lipid-lowering therapy in diabetic patients.
- Analysis of the efficacy of various lipid-lowering medications, including statins and fibrates.
- Examination of treatment goals set by major health organizations like NCEP ATP III and ADA.
Main Results:
- Lipid-lowering therapy has been shown to slow atherosclerosis and reduce cardiovascular events in diabetic individuals.
- Statins are effective first-line treatments, significantly reducing LDL-C and triglycerides.
- Fibrates play a key role in managing hypertriglyceridaemia, and newer agents like rosuvastatin show enhanced efficacy.
Conclusions:
- Aggressive management of lipid abnormalities is crucial for reducing CHD risk in type 2 diabetes.
- Statins and fibrates are vital tools in achieving treatment goals for diabetic dyslipidaemia.
- Targeting specific lipid profiles in diabetic patients can significantly lower cardiovascular mortality.
Abstract:
Coronary heart disease (CHD) is the leading cause of death in patients with type 2 diabetes. The hyperglycaemia that characterises this disease is often accompanied by a cluster of other risk factors, such as dyslipidaemia and hypertension, and effective management of the patient with diabetes requires treatment directed at correcting all of the abnormalities that increase cardiovascular risk. Approximately 90% of patients with diabetes have type 2 disease, and dyslipidaemia in these patients is characterised by elevated plasma triglycerides and very-low-density lipoproteins (VLDL), by reduced high-density lipoprotein cholesterol (HDL-C), and by a shift in LDL distribution towards small, dense particles. All of these lipid abnormalities are important risk factors for CHD. Retrospective subgroup analysis and prospective studies have shown that lipid-lowering therapy can slow the progression of atherosclerosis and reduce the risk for cardiovascular events in patients with diabetes, and both the National Cholesterol Education Program Adult Treatment Panel III and American Diabetes Association have established aggressive treatment goals for lipid-lowering therapy in these patients. All of the major medications used to treat hyperlipidaemia in other populations (niacin, fibrates, bile acid sequestrants and statins) have been used effectively to improve the plasma lipid profile in patients with diabetes. Statins are generally accepted as first-line treatment for these patients, although fibrates also have an important role in patients with pronounced hypertriglyceridaemia. Statins significantly reduce low-density lipoprotein cholesterol (LDL-C) in a broad range of patients. These agents also have substantial effects on plasma triglycerides and, in patients with hypertriglyceridaemia, lower very-low-density lipoprotein cholesterol (VLDL-C) to approximately the same extent as LDL-C. In this regard, the new agent rosuvastatin has been shown, in recent trials, to produce greater decreases in these lipoproteins than currently marketed compounds. Aggressive use of agents that attack the lipid abnormalities characteristic of patients with type 2 diabetes has the potential to significantly reduce CHD risk in these individuals.